🔎 Trials Near Me

Akèy › Kansè trakt bilè › Florid

Etid klinik pou Kansè trakt bilè nan Florid

14 etid pou Kansè trakt bilè ap chèche patisipan nan sit nan Florid.

Vil nan Florid

Tèks ofisyèl etid la (Anglè)

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus, Fort Myers
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06760819

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  • Research Site, Gainesville
  • Research Site, Jacksonville
  • Research Site, Miami
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07221253

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

  • University of Florida College of Medicine ( Site 0281), Gainesville
  • Mount Sinai Cancer Center ( Site 0287), Miami Beach
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06428409

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  • AdventHealth Hematology and Oncology, Orlando
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06282575

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • University of Miami, Miami
  • Sarah Cannon Research Institute - Lake Nona Florida, Orlando
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

  • Avenzo Therapeutics Recruiting Site, Orlando
  • Avenzo Therapeutics Recruiting Site, Sarasota
  • Avenzo Therapeutics Recruiting Site, Tampa
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Sep 4, 2026 · NCT07038343

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  • Research Site, Fort Myers
  • Research Site, Jacksonville
  • Research Site, St. Petersburg
  • ak 2 plis
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Aug 19, 2026 · NCT06467357

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • AdventHealth Celebration, Celebration
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

  • Mount Sinai Medical Center, Miami Beach
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 30, 2026 · NCT06622057

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • University of Miami Hospital and Clinics, Miami
Ap rekriteFaz 2
Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

  • Florida Cancer Specialists, Sarasota
  • Moffitt Cancer Center, Tampa
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT07458347

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

  • Sylvester Comprehensive Cancer Center - University of Miami Health System, Miami
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06239194

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

  • Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics), Miami
  • Moffitt Cancer Center, Tampa
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 2, 2026 · NCT05733598

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.